Mergers and Acquisitions

Date: 2017-08-31

Type of information: Company acquisition

Acquired company: Bertin Pharma (France)

Acquiring company: Oncodesign (France)

Amount: undisclosed


  • • On August 31, 2017, Oncodesign announced an agreement to acquire Bertin Pharma’s metabolism, pharmacokinetics, bioanalysis and translational medicine service activities. This deal covers the transfer of a team of 46 highly qualified multidisciplinary employees to support the proprietary or third-party discovery and development of new drugs in areas such as immunology and infectious diseases. The scope of the transfer includes capacity to study the absorption, distribution, metabolism and excretion of therapeutic molecules (ADME), regulated bioanalysis, and centralized biobanking to manage biological samples, both with and without the risk of infection.
  • The acquisition will be funded by a bank loan. PK/PDesign, a newly formed wholly-owned subsidiary, will hold the new activities acquired within the Oncodesign group.
  • • On May 10, 2017, Oncodesign has announced the opening of a period of exclusive negotiations to acquire Bertin Pharma's service businesses in Metabolism, Pharmacokinetics, Bio-analysis and Translational Medicine. These activities in the fields of immunology and infectiology will be an ideal fit with Oncodesign group's current service offering. The business portfolio under discussion has some 48 employees, with 2016 revenue of €5.3 million. It complements Oncodesign in many technological and regulatory areas and would contribute to the acceleration of Oncodesign group's 2017-2020 strategic plan for its service business. This project, which has been the subject of an information and consultation process with employee representative bodies, could be completed in the summer of 2017.


  • In 2016, the business acquired by Oncodesign generated EBITDA of €0.8 million on revenues of €5.3 million. The activities acquired, currently conducted at four sites (Saclay, Fontenay aux Roses, Marcoule and Orléans) will all be pooled at Oncodesign’s Les Ulis facility in the short to medium term. Oncodesign thus plans to strengthen significantly its presence at the Paris-Saclay platform. Furthermore, the Commissariat à l’Énergie Atomique (CEA) is a longstanding partner of Bertin Pharma. Indeed, teams at the Saclay, Fontenay aux Roses (IDMIT) and Marcoule sites are housed in CEA facilities and are integrated with its research teams. Oncodesign intends to step up its cooperation with the CEA as a research partner, and this will be facilitated by the Group’s presence at the Paris-Saclay platform. In addition to the scientific and technical staff, sales and marketing teams will strengthen Oncodesign’s capabilities. Xavier Morge, Bertin Pharma’s Chief Executive Officer, has been appointed Oncodesign’s Head of Business Development and Marketing. Xavier gained a PhD in pharmacy (University of Paris XI) and holds an MBA (IAE Paris). He co-founded SPI-Bio within the CEA, and served as its Chief Executive Officer. He kept this role when SPI-Bio joined Bertin Technologies, then Bertin Pharma in 2010 as part of the CNIM group, doubling its global sales.

Related: Technology - Services - Immunological diseases

Is general: Yes